Do analysts prefer CALT or TENX?

Tenax Therapeutics has a consensus target price of $38.00, indicating a potential upside of 178.59%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tenax Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Which has stronger valuation and earnings, MPLT or TENX?

Tenax Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A Tenax Therapeutics N/A N/A -$52.60M -$1.40 N/A

Is MPLT or TENX more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Tenax Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A N/A N/A Tenax Therapeutics N/A -56.32% -53.12%

Does the media prefer MPLT or TENX?

In the previous week, Maplight Therapeutics had 3 more articles in the media than Tenax Therapeutics. MarketBeat recorded 5 mentions for Maplight Therapeutics and 2 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.50 beat Maplight Therapeutics' score of 0.07 indicating that Tenax Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, COAG or TENX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A Tenax Therapeutics N/A N/A -$52.60M -$1.40 N/A

Is COAG or TENX more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Tenax Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Tenax Therapeutics N/A -56.32% -53.12%

Does the media prefer COAG or TENX?

In the previous week, Hemab Therapeutics had 13 more articles in the media than Tenax Therapeutics. MarketBeat recorded 15 mentions for Hemab Therapeutics and 2 mentions for Tenax Therapeutics. Hemab Therapeutics' average media sentiment score of 1.05 beat Tenax Therapeutics' score of 0.50 indicating that Hemab Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TENX or XERS?

In the previous week, Tenax Therapeutics and Tenax Therapeutics both had 2 articles in the media. Xeris Biopharma's average media sentiment score of 1.53 beat Tenax Therapeutics' score of 0.50 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to TENX or WVE?

In the previous week, Tenax Therapeutics had 1 more articles in the media than WAVE Life Sciences. MarketBeat recorded 2 mentions for Tenax Therapeutics and 1 mentions for WAVE Life Sciences. Tenax Therapeutics' average media sentiment score of 0.50 equaled WAVE Life Sciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tenax Therapeutics (TENX) Competitors

$13.64 +1.39 (+11.35%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$13.33 -0.31 (-2.27%)

As of 06/23/2026 07:40 PM Eastern

Compare

TENX vs. CALT, MPLT, COAG, XERS, and WVE

Should you buy Tenax Therapeutics stock or one of its competitors? MarketBeat compares Tenax Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tenax Therapeutics include Calliditas Therapeutics AB (publ) (CALT), Maplight Therapeutics (MPLT), Hemab Therapeutics (COAG), Xeris Biopharma (XERS), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.

How does Tenax Therapeutics compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Tenax Therapeutics has a consensus target price of $38.00, indicating a potential upside of 178.59%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Tenax Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A

In the previous week, Tenax Therapeutics had 2 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for Tenax Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Tenax Therapeutics' average media sentiment score of 0.50 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Tenax Therapeutics	Positive

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 3.7% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

Tenax Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Tenax Therapeutics' return on equity of -56.32% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Tenax Therapeutics	N/A	-56.32%	-53.12%

Summary

Tenax Therapeutics beats Calliditas Therapeutics AB (publ) on 11 of the 16 factors compared between the two stocks.

How does Tenax Therapeutics compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Maplight Therapeutics' return on equity of 0.00% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Tenax Therapeutics	N/A	-56.32%	-53.12%

In the previous week, Maplight Therapeutics had 3 more articles in the media than Tenax Therapeutics. MarketBeat recorded 5 mentions for Maplight Therapeutics and 2 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.50 beat Maplight Therapeutics' score of 0.07 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenax Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.7% of Tenax Therapeutics shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by company insiders. Comparatively, 3.7% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tenax Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A

Maplight Therapeutics presently has a consensus price target of $38.00, indicating a potential upside of 32.68%. Tenax Therapeutics has a consensus price target of $38.00, indicating a potential upside of 178.59%. Given Tenax Therapeutics' higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Maplight Therapeutics beats Tenax Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Tenax Therapeutics compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Hemab Therapeutics presently has a consensus target price of $41.40, indicating a potential upside of 42.02%. Tenax Therapeutics has a consensus target price of $38.00, indicating a potential upside of 178.59%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tenax Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A

1.7% of Tenax Therapeutics shares are held by institutional investors. 3.7% of Tenax Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Hemab Therapeutics' return on equity of 0.00% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Tenax Therapeutics	N/A	-56.32%	-53.12%

In the previous week, Hemab Therapeutics had 13 more articles in the media than Tenax Therapeutics. MarketBeat recorded 15 mentions for Hemab Therapeutics and 2 mentions for Tenax Therapeutics. Hemab Therapeutics' average media sentiment score of 1.05 beat Tenax Therapeutics' score of 0.50 indicating that Hemab Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenax Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tenax Therapeutics beats Hemab Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Tenax Therapeutics compare to Xeris Biopharma?

Tenax Therapeutics (NASDAQ:TENX) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Tenax Therapeutics currently has a consensus price target of $38.00, indicating a potential upside of 178.59%. Xeris Biopharma has a consensus price target of $10.80, indicating a potential upside of 50.00%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Tenax Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Xeris Biopharma has a net margin of 3.81% compared to Tenax Therapeutics' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-56.32%	-53.12%
Xeris Biopharma	3.81%	735.00%	3.24%

In the previous week, Tenax Therapeutics and Tenax Therapeutics both had 2 articles in the media. Xeris Biopharma's average media sentiment score of 1.53 beat Tenax Therapeutics' score of 0.50 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Xeris Biopharma has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A
Xeris Biopharma	$291.85M	4.26	$550K	$0.06	120.00

Tenax Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 3.7% of Tenax Therapeutics shares are held by insiders. Comparatively, 4.4% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Xeris Biopharma beats Tenax Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Tenax Therapeutics compare to WAVE Life Sciences?

Tenax Therapeutics (NASDAQ:TENX) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

In the previous week, Tenax Therapeutics had 1 more articles in the media than WAVE Life Sciences. MarketBeat recorded 2 mentions for Tenax Therapeutics and 1 mentions for WAVE Life Sciences. Tenax Therapeutics' average media sentiment score of 0.50 equaled WAVE Life Sciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tenax Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. Tenax Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A
WAVE Life Sciences	$42.73M	27.20	-$204.38M	-$1.06	N/A

Tenax Therapeutics presently has a consensus price target of $38.00, indicating a potential upside of 178.59%. WAVE Life Sciences has a consensus price target of $26.41, indicating a potential upside of 337.28%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe WAVE Life Sciences is more favorable than Tenax Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 3.7% of Tenax Therapeutics shares are held by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Tenax Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, suggesting that its share price is 233% less volatile than the broader market.

Tenax Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Tenax Therapeutics' return on equity of -56.32% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-56.32%	-53.12%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Summary

WAVE Life Sciences beats Tenax Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Tenax Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TENX vs. The Competition

Export

Metric	Tenax Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$324.93M	$3.45B	$6.44B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-9.74	19.75	24.90	23.99
Price / Sales	N/A	330.90	527.78	108.89
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	1.31	8.29	10.79	6.50
Net Income	-$52.60M	$23.85M	$3.56B	$336.88M
7 Day Performance	14.91%	2.87%	1.00%	-0.14%
1 Month Performance	12.45%	2.19%	0.42%	0.77%
1 Year Performance	138.05%	55.48%	29.70%	28.49%

Tenax Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TENX Tenax Therapeutics	2.9446 of 5 stars	$13.64 +11.3%	$38.00 +178.6%	+142.7%	$324.93M	N/A	N/A	9	Analyst Forecast Gap Down
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
MPLT Maplight Therapeutics	3.5712 of 5 stars	$27.16 -2.9%	$37.78 +39.1%	N/A	$1.19B	N/A	N/A	109	News Coverage Analyst Forecast Gap Down
COAG Hemab Therapeutics	4.7948 of 5 stars	$25.51 +1.7%	$41.75 +63.7%	N/A	$1.19B	N/A	N/A	72	News Coverage Positive News
XERS Xeris Biopharma	3.3159 of 5 stars	$6.90 +0.3%	$10.80 +56.5%	+55.2%	$1.19B	$291.85M	115.00	290	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TENX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tenax Therapeutics (TENX) Competitors

TENX vs. CALT, MPLT, COAG, XERS, and WVE

How does Tenax Therapeutics compare to Calliditas Therapeutics AB (publ)?

Summary

How does Tenax Therapeutics compare to Maplight Therapeutics?

Summary

How does Tenax Therapeutics compare to Hemab Therapeutics?

Summary

How does Tenax Therapeutics compare to Xeris Biopharma?

Summary

How does Tenax Therapeutics compare to WAVE Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TENX vs. The Competition

Tenax Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tenax Therapeutics (TENX) Competitors

TENX vs. CALT, MPLT, COAG, XERS, and WVE

How does Tenax Therapeutics compare to Calliditas Therapeutics AB (publ)?

Do analysts prefer CALT or TENX?

Which has higher earnings and valuation, CALT or TENX?

Does the media favor CALT or TENX?

Do insiders & institutionals believe in CALT or TENX?

Which has more risk & volatility, CALT or TENX?

Is CALT or TENX more profitable?

Summary

How does Tenax Therapeutics compare to Maplight Therapeutics?

Is MPLT or TENX more profitable?

Does the media prefer MPLT or TENX?

Do insiders and institutionals believe in MPLT or TENX?

Which has stronger valuation and earnings, MPLT or TENX?

Do analysts prefer MPLT or TENX?

Summary

How does Tenax Therapeutics compare to Hemab Therapeutics?

Do analysts recommend COAG or TENX?

Which has higher valuation and earnings, COAG or TENX?

Do institutionals & insiders have more ownership in COAG or TENX?

Is COAG or TENX more profitable?

Does the media prefer COAG or TENX?

Summary

How does Tenax Therapeutics compare to Xeris Biopharma?

Do analysts recommend TENX or XERS?

Is TENX or XERS more profitable?

Does the media refer more to TENX or XERS?

Which has preferable earnings & valuation, TENX or XERS?

Which has more risk and volatility, TENX or XERS?

Do institutionals and insiders have more ownership in TENX or XERS?

Summary

How does Tenax Therapeutics compare to WAVE Life Sciences?

Does the media refer more to TENX or WVE?

Which has stronger valuation & earnings, TENX or WVE?

Do analysts recommend TENX or WVE?

Do insiders and institutionals have more ownership in TENX or WVE?

Which has more volatility and risk, TENX or WVE?

Is TENX or WVE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TENX vs. The Competition

Tenax Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools